NCT00916370已完成3 期
SPIRIT PRIME Clinical Trial.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 525
- 试验地点
- 121
- 主要终点
- Target Lesion Failure (TLF)
研究概览
简要总结
To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be at least 18 years of age.
- •Subject or a legally authorized representative must provide written informed consent prior to any study related procedure, per site requirements.
- •Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram (ECG) consistent with ischemia).
- •Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
- •Subject must agree to undergo all protocol-required follow-up procedures.
- •Subject must agree not to participate in any other clinical study for a period of one year following the index procedure.
- •Angiographic Inclusion Criteria
- •One or two de novo target lesions each in a different epicardial vessel.
- •If there are two target lesions, both lesions must satisfy the angiographic eligibility criteria for that registry.
- •o Multiple focal de novo lesions in a target vessel that can be covered by a single stent are allowed.
- •The target lesion(s) must be located in a major artery or branch with a visually estimated diameter stenosis of ≥ 50% and < 100% with a TIMI flow of ≥
- •Target lesion(s) must be located in a native coronary artery with reference vessel diameter (RVD) by visual estimation of:
- •≥ 2.25 mm and ≤ 4.25 mm for treatment by the core size XIENCE PRIME EECS
- •≥ 2.5 mm and ≤ 4.25 mm for treatment by the XIENCE PRIME LL EECS
- •Target lesion(s) must be located in a native coronary artery with length by visual estimation of:
- •≤ 22 mm for treatment by the core size XIENCE PRIME EECS
- •> 22 mm and ≤ 32 mm for treatment by the XIENCE PRIME LL EECS
排除标准
- •Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the index procedure (CK-MB ≥ 2 times upper limit of normal) and CK and CK-MB have not returned to within normal limits at the time of procedure.
- •The subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.
- •Subject has current unstable cardiac arrhythmias associated with hemodynamic instability.
- •Subject has a known left ventricular ejection fraction (LVEF) < 30% (LVEF may be obtained at the time of the index procedure if the value is unknown and if necessary).
- •Subject has received coronary brachytherapy in any epicardial vessel (target or non target).
- •Subject has received any organ transplant or is on a waiting list for any organ transplant.
- •Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or within one year after the index procedure.
- •Subject is receiving or scheduled to receive planned radiotherapy to the chest/mediastinum.
- •Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.).
- •Subject is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).
- •Subject will require Low Molecular Weight Heparin (LMWH) post-procedure.
- •Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.
- •Elective surgery is planned within 12 months after the procedure that will require discontinuing either aspirin or clopidogrel.
- •Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a white blood cell (WBC) of < 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis).
- •Subject has known renal insufficiency (examples being but not limited to estimated glomerular filtration rate (eGFR) < 60 ml/kg/m2, serum creatinine level ≥ 2.5 mg/dL, or on dialysis).
- •Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- •Subject has had a cerebrovascular accident/stroke or transient ischemic neurological attack (TIA) within the past six months.
- •Subject has had a significant gastro-intestinal or significant urinary bleed within the past six months.
- •Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion.
- •Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
- •Subject is currently participating in another clinical study that has not yet completed its primary endpoint.
- •Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
- •Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual estimation.
- •Target lesion located within an arterial or saphenous vein graft or distal to a diseased (vessel irregularity per angiogram and > 20% stenosed lesion) arterial or saphenous vein graft.
- •Target lesion involving a bifurcation with a side branch ≥ 2 mm in diameter and/or ostial lesion > 40% stenosed or side branch requiring protection guide wire, or side branch requiring dilatation.
- •Target lesion with total occlusion (TIMI flow 0), prior to crossing with the wire.
- •Another lesion requiring revascularization is located in the same epicardial vessel of the target lesion.
- •Restenotic target lesion.
- •Aorto-ostial target lesion (within 3 mm of the aorta junction).
- •Target lesion is in a left main location.
- •Target lesion located within 2 mm of the origin of the LAD or LCX.
- •Extreme angulation (≥ 90 °) or excessive tortuosity (≥ two 45° angles) proximal to or within the lesion.
- •Heavy calcification proximal to or within the target lesion.
- •Target vessel contains thrombus as indicated in the angiographic images.
- •Target lesion has a high probability that a procedure other than pre-dilatation and stenting will be required at the time of index procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon).
- •Target vessel is previously treated with any type of PCI (e.g. balloon angioplasty, stent, cutting balloon, atherectomy) < 9 months prior to index procedure.
- •Non-target vessel is previously treated with any type of PCI < 90 days prior to the index procedure.
- •Additional clinically significant lesion(s) (e.g. %DS ≥ 50%) in a target vessel or side branch for which PCI may be required < 90 days after the index procedure.
结局指标
主要结局
Target Lesion Failure (TLF)
时间窗: 3 years
The composite rate of: Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.
次要结局
- Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)(3 years)
- Clinically Indicated-Target Lesion Revascularization(3 years)
- Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)(3 years)
- Device Success (Lesion Basis)(From the start of index procedure to end of index procedure)
- All Death (Cardiac, Vascular, Non-cardiovascular)(3 years)
- Non-target Vessel MI (Q-wave, Non Q-wave)(3 years)
- All TLR (CI and Non-CI)(3 years)
- All TVR (CI and Non-CI)(3 years)
- All Death/All MI/All Coronary Revascularization(3 years)
- Procedure Time(From insertion to withdrawal of guide catheter)
- Cardiac Death/ All MI(30 days)
- Cardiac Death/ All MI/CI-TLR(3 years)
- Procedural Success (Subject Basis)(From the start of index procedure to end of index procedure)
- All Coronary Revascularization (TVR and Non-TVR)(3 years)
- Cardiac Death/All MI(3 years)
- Stent Thrombosis(Overall (0 - 1123 days))
研究者
研究点 (121)
Loading locations...
相似试验
尚未招募
2 期
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal CancerEfficacy, SelfSafety IssuesColo-rectal CancerNCT06491355Sir Run Run Shaw Hospital72
Enrolling By Invitation
2 期
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesNon Small Cell Lung CancerNCT06250777Yonsei University27
已完成
2 期
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsEsophageal Squamous Cell CarcinomaNCT04548440Sun Yat-sen University50
Unknown
1 期
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid TumorsAdvanced Tumor of Digestive Tract or Urinary SystemNCT05499715Chinese Academy of Medical Sciences48
招募中
2 期
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCALK Positive Non-small Cell Lung CancerNCT06092086Guangdong Association of Clinical Trials126